Production (Stage)
Avalo Therapeutics, Inc.
AVTX
$3.75
-$0.16-4.09%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -66.37% | 5.51% | -100.00% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -66.37% | 5.51% | -100.00% | -- |
| Cost of Revenue | 1,423.71% | 1,206.13% | 2,606.67% | -33.62% | -92.21% |
| Gross Profit | -1,423.71% | -3,736.73% | -156,075.00% | 21.95% | 91.39% |
| SG&A Expenses | 73.69% | 95.55% | 72.13% | 86.61% | 17.91% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 180.53% | 212.42% | 228.90% | 21.53% | -43.57% |
| Operating Income | -180.53% | -254.87% | -242.96% | -32.46% | 40.53% |
| Income Before Tax | 89.17% | -330.78% | 541.05% | 1,302.91% | -1,119.29% |
| Income Tax Expenses | 14.29% | 1,366.67% | -275.00% | 0.00% | -12.50% |
| Earnings from Continuing Operations | 89.16% | -332.65% | 540.65% | 1,301.79% | -1,118.38% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 89.16% | -332.65% | 540.65% | 1,301.79% | -1,118.38% |
| EBIT | -180.53% | -254.87% | -242.96% | -32.46% | 40.53% |
| EBITDA | -179.77% | -257.15% | -245.83% | -32.76% | 40.69% |
| EPS Basic | 99.11% | 66.03% | 103.67% | 100.66% | 30.75% |
| Normalized Basic EPS | 98.85% | 34.90% | 115.49% | 103.00% | 46.43% |
| EPS Diluted | 99.11% | 83.01% | 89.44% | 97.26% | 30.75% |
| Normalized Diluted EPS | 98.85% | 34.90% | 107.97% | 103.00% | 46.43% |
| Average Basic Shares Outstanding | 1,123.52% | 1,167.19% | 2,745.72% | 40,085.40% | 1,661.07% |
| Average Diluted Shares Outstanding | 1,123.52% | 1,167.19% | 5,433.09% | 40,085.40% | 1,661.07% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |